NASDAQ:OSUR - OraSure Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$15.46 -0.06 (-0.39 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$15.52
Today's Range$15.29 - $15.75
52-Week Range$12.86 - $23.01
Volume291,500 shs
Average Volume544,220 shs
Market Capitalization$946.35 million
P/E Ratio30.26
Dividend YieldN/A
Beta1.61
OraSure Technologies logoOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Debt-to-Equity RatioN/A
Current Ratio9.58
Quick Ratio8.60

Price-To-Earnings

Trailing P/E Ratio30.26
Forward P/E Ratio42.94
P/E Growth3.44

Sales & Book Value

Annual Sales$167.06 million
Price / Sales5.66
Cash Flow$0.6154 per share
Price / Cash25.12
Book Value$4.26 per share
Price / Book3.63

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$30.94 million
Net Margins8.38%
Return on Equity5.85%
Return on Assets5.22%

Miscellaneous

Employees377
Outstanding Shares61,170,000
Market Cap$946.35 million

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings data on Wednesday, August, 8th. The medical instruments supplier reported $0.07 EPS for the quarter, topping the consensus estimate of $0.04 by $0.03. The medical instruments supplier had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.09 EPS. View OraSure Technologies' Earnings History.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for OraSure Technologies.

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies updated its third quarter earnings guidance on Wednesday, August, 8th. The company provided earnings per share guidance of $0.10-0.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.11. The company issued revenue guidance of $44-45.5 million, compared to the consensus revenue estimate of $43.72 million.

What price target have analysts set for OSUR?

3 brokers have issued 12 month target prices for OraSure Technologies' stock. Their forecasts range from $23.00 to $24.00. On average, they expect OraSure Technologies' share price to reach $23.50 in the next year. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

What is the consensus analysts' recommendation for OraSure Technologies?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

Who are some of OraSure Technologies' key competitors?

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the folowing people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 57)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 64)
  • Mr. Brian L. Smith, Exec. VP & Bus. Unit Leader of Molecular Solutions - DNA Genotek, Inc. (Age 59)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 50)

Has OraSure Technologies been receiving favorable news coverage?

Media headlines about OSUR stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for OraSure Technologies.

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.89%), Renaissance Technologies LLC (6.38%), Dimensional Fund Advisors LP (4.63%), Fred Alger Management Inc. (4.41%), Peregrine Capital Management LLC (1.72%) and Emerald Advisers Inc. PA (1.65%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

Which institutional investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Fisher Asset Management LLC, Renaissance Technologies LLC, Thompson Siegel & Walmsley LLC, Royce & Associates LP, Citadel Advisors LLC, Voya Investment Management LLC and Wells Fargo & Company MN. Company insiders that have sold OraSure Technologies company stock in the last year include Brian Smith, Charles W Patrick, Douglas A Michels and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

Which institutional investors are buying OraSure Technologies stock?

OSUR stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., BlackRock Inc., Casdin Capital LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, American Capital Management Inc., Penn Capital Management Co. Inc. and Bank of America Corp DE. View Insider Buying and Selling for OraSure Technologies.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $15.46.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $946.35 million and generates $167.06 million in revenue each year. The medical instruments supplier earns $30.94 million in net income (profit) each year or $0.51 on an earnings per share basis. OraSure Technologies employs 377 workers across the globe.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]


MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  424 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  695
MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel